Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Account Payables
Amounts the company owes suppliers for goods and services received.
Puma Biotechnology, Inc.NASDAQ: PBYI
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 35.5% from a year ago
Account payables stood at $8.17M at the end of Q1 FY2026, up 35.5% from a year earlier and up 61.5% from the prior quarter. Over 3 fiscal years it compounded at -7.7% a year.
Context
- Account payables amounted to 4.2% of total assets at the end of Q1 FY2026, up 1.2 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +35.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 5.06M USD
- Year-over-year change
- -8.2%
- 4-year CAGR
- -18.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.06M | -8.2% |
| FY2024 | 2024-12-31 | 5.51M | -20.0% |
| FY2023 | 2023-12-31 | 6.89M | +7.0% |
| FY2022 | 2022-12-31 | 6.44M | -42.4% |
| FY2021 | 2021-12-31 | 11.17M | — |
Account Payables vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +35.5% is the 4th highest of 10, against a peer median of +13.0%.
- Account payables amounts to 4.2% of total assets for PBYI, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $12.09M USD | -46.1% | +64.3% | 1.6% | |
| Mar 2026 | $9.6M USD | +33.4% | +36.4% | 4.2% | |
| Mar 2026 | $8.73M USD | +100.0% | +24.2% | 2.5% | |
| Mar 2026 | $8.17M USD | +35.5% | -7.7% | 4.2% | |
| Mar 2026 | $5.48M USD | +51.0% | +60.5% | 11.1% | |
| Mar 2026 | $4.29M USD | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $2.97M USD | +13.0% | -32.4% | 2.2% | |
| Mar 2026 | $2.9M USD | -43.9% | +42.6% | 0.7% | |
| Mar 2026 | CA$2.68M CAD | +244.2% | +28.8% | 32.9% | |
| Sep 2026 | $1.65M USD | -26.0% | -35.7% | 0.2% | |
NBPNovaBridge Biosciences | Dec 2025 | $0 USD | — | — | 0.0% |
| Peer median (excluding PBYI) | — | +13.0% | +28.8% | 2.1% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.13M | 76.2M | 84.59M | 69.22M | 29.64M |
| Short-term Investments | 18.98M | 4.87M | 11.35M | 31.75M | 67.89M |
| Net Receivables | 32.53M | 42.27M | 48.49M | 32.01M | 53.65M |
| Inventory | 7.11M | 4.53M | 7.08M | 8.72M | 5.52M |
| Other Current Assets | 11.43M | 1.95M | 260K | 3.7M | 4M |
| Total Current Assets | 140.02M | 134.28M | 156.19M | 147.66M | 162.69M |
| Property, Plant & Equipment (Net) | 15.77M | 12.51M | 8.65M | 5.09M | 5.56M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 66.13M | 70.61M | 60.87M | 51.13M | 41.39M |
| Long-term Investments | 0 | 0 | 2.09M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 7.08M | 3.83M |
| Other Non-current Assets | 4.67M | 4.66M | 2.73M | 2.38M | 2.83M |
| Total Non-current Assets | 86.56M | 87.78M | 74.34M | 65.68M | 53.62M |
| Total Assets | 226.59M | 222.06M | 230.53M | 213.33M | 216.3M |
| Account Payables | 11.17M | 6.44M | 6.89M | 5.51M | 5.06M |
| Short-term Debt | 0 | 0 | 34M | 45.33M | 22.52M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.22M | 13.34M | 43.42M | 15.18M | 16.5M |
| Total Current Liabilities | 109.59M | 77.48M | 99.38M | 96.11M | 81.25M |
| Long-term Debt | 97.09M | 98.31M | 65.66M | 21.72M | 4.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.38M | 12.83M | 5.01M | 1.88M | 0 |
| Total Non-current Liabilities | 119.45M | 122.97M | 77.7M | 25.1M | 4.71M |
| Total Liabilities | 229.03M | 200.45M | 177.09M | 121.21M | 85.96M |
| Common Stock | 4K | 5K | 5K | 5K | 5K |
| Retained Earnings | (1.37B) | (1.37B) | (1.35B) | (1.31B) | (1.28B) |
| Accumulated OCI | (2K) | 0 | (4K) | 6K | 36K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (2.45M) | 21.61M | 53.44M | 92.13M | 130.34M |
| Total Debt | 116.64M | 114.28M | 111.49M | 74.08M | 28.55M |
| Net Debt | 53.51M | 38.08M | 26.91M | 4.86M | (1.09M) |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.